Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23684362 | 0.81 | HRH3 (0.41) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL8188548 | 0.70 | HRH3 (0.43) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL13989173 | 0.68 | CYP2C19 (0.34) | CD274CYP4F2CYP4A11 | |
| SCHEMBL13301307 | 0.68 | CA1 (0.52) | CD274RXRAGRIN1GRIN2B | |
| SCHEMBL22070632 | 0.68 | CYP4F2 (0.66) | CYP4F2CYP4A11 | |
| SCHEMBL17585078 | 0.66 | HRH3 (0.58) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL13097235 | 0.66 | HRH3 (0.49) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL17585079 | 0.66 | HRH3 (0.54) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL23684209 | 0.66 | HRH3 (0.51) | HRH3CD274NOS3NOS1NOS2 | |
| SCHEMBL1020646 | 0.65 | CD274 (0.61) | HRH3CD274HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885CD274 4074/4885NOS3 505/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | HRH3 183/4885CD274 4074/4885NOS3 505/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | HRH3 183/4885CD274 4074/4885NOS3 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.